| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
|
Product Name
|
Naltrexone Hydrochloride
|
|
Other Name
|
17-cyclopropyl methyl-4
|
|
CAS NO.
|
16676-29-2
|
|
Grade
|
Medicine grade
|
|
Appearance
|
White Powder
|
|
Specification
|
99%
|
|
Storage
|
Keep in cool & dry place, stay away from strong light and heat
|
|
Shelf Life
|
24 months
|
The main use of naltrexone is for the treatment of alcoholism. Naltrexone has been shown to decrease the amount and frequency of drinking. It does not appear to change the percentage of people drinking. Its overall benefit has been described as "modest".
Acamprosate may work better than naltrexone for eliminating drinking, while naltrexone may decrease the desire for alcohol to a greater extent.
The Sinclair method is a method of using antagonists such as naltrexone to treat alcoholism. The patient takes the medication about an hour (and only then) before drinking to avoid side effects that arise from chronic use. The blocks the positive reinforcement effects of alcohol and allows the person to stop or reduce drinking.
A 2011 review of studies suggested that naltrexone, when taken by mouth, was not superior to placebo or to no medication. Because of the poor quality of the reviewed studies, the authors found insufficient evidence to support naltrexone therapy when taken by mouth for disorder.While some patients do well with the oral formulation, it must be taken daily, and a patient whose cravings become overwhelming can obtain intoxication simply by skipping a dose. Due to this issue, the usefulness of oral naltrexone in disorders is limited by the low retention in treatment. Oral naltrexone remains an ideal treatment only for a small part of the addicted population, usually those with a stable social situation and motivation. With additional contingency management support, naltrexone is effective in a broader population.
Extended-release depot injections of naltrexone, administered once per month, have proven somewhat effective in treating abuse, an approach that avoids the compliance issue that arises with oral formulations.
The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping.
These adverse effects are analogous to the symptoms of withdrawal, as the mu receptor blockade will increase GI motility.
Naltrexone has been reported to cause liver damage (when given at doses higher than recommended). Due to these reports, some physicians may check liver function tests prior to starting naltrexone, and periodically thereafter. Concerns for liver toxicity initially arose from a study of non-addicted obese patients receiving 300 mg of naltrexone. Subsequent studies have suggested limited toxicity in other patient populations.
Naltrexone should not be started until several (typically 7-10) days of abstinence from has been achieved. This is due to the risk of acute withdrawal if naltrexone is taken, as naltrexone will displace from their receptors. The time of abstinence may be shorter than 7 days, depending on the half-life of the specific taken. Some physicians use a naloxone challenge to determine whether an individual has any remaining. The challenge involves giving a test dose of naloxone and monitoring for withdrawal. If withdrawal occurs, naltrexone should not be started.
It is important that a person does not attempt to use while using naltrexone. Although naltrexone blocks the receptor, it is possible to override this blockade with high doses. This is quite dangerous, and may lead to overdose, respiratory depression, and death. Similarly, a person will not show a normal response to pain medications when taking naltrexone. In a supervised medical setting pain relief is possible, but may require higher than usual doses, and the individual should be closely monitored for respiratory depression. All individuals taking naltrexone are encouraged to keep a card or a note in their wallet in case of an injury or another medical emergency. This is to let medical personnel know that special procedures are required if based painkillers are to be used.
There has been some controversy regarding the use of receptor antagonists such as naltrexone in the long-term management of dependence, due to the effect of these agents in sensitizing receptors. That is, after therapy, the receptors continue to have increased sensitivity for a period during which the patient is at increased risk of overdose.This effect reinforces the necessity of monitoring therapy, and provision of patient support measures by medical practitioners.
|
Packing
|
1kg/bag ,25kg/bag;25kg/drum; according to your requirements |
| Transit | Fedex, TNT,DHL,EMS,and so on. |
| Port | Shanghai/Tianjin/Dalian/Beijing/Xi'an |
| Lead Time | 3-5 working days upon received the payment |
| For mass orders, it will be delivered by air or sea. Depending on your location, please allow 1-5 business days for your order to arrive. For small order, please expect 3-7 days by UPS DHL EMS. For mass order, please allow 5-8 days by Air, 15-30 days by Sea. |
){kind=link}